Last reviewed · How we verify
NCT03588767
Endocrine Response of the Organism to Polytrauma
NA trial testing Vitamin D3 + anabolic substance in Polytrauma in 60 participants. Completed in 31 January 2021.
30 May 2020
Quick facts
| Lead sponsor | University Hospital Ostrava |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 31 May 2017 |
| Primary completion | 30 May 2020 |
| Estimated completion | 31 January 2021 |
| Sites | 1 location across Czechia |
Drugs / interventions tested
- Vitamin D3 + anabolic substance — full drug profile →
- No Vitamin D3 + anabolic substance
Conditions studied
- Polytrauma — all drugs for Polytrauma →
Sponsor
University Hospital Ostrava
Who can join
Adults 18 to 60, any sex, with Polytrauma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The serious injury causes a complex acute response of the organism to the injury in affected patients, which is manifested in the neuroendocrine, immune and metabolic areas, with an often persisting catabolic state, with a subsequent negative impact upon bone metabolism. By a timely administration of the D3 vitamin and an anabolic, we attempt to achieve an earlier activation of the anabolic phase of patient resuscitation after serious trauma regarding the monitoring of laboratory values of bone metabolism.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03588767
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Polytrauma
Currently open trials in the same condition.
- NCT07480655 — Pv-aCO₂ Gap-Guided Resuscitation in Adult Polytrauma Patients: A Prospective Randomized Controlled Trial · Phase 4 · recruiting
- NCT06969404 — Prognostic Value of Capillary Lactatemia in Potentially Severe Polytrauma Patients · NA · recruiting
- NCT06622317 — Abdominal Aortic Junction Tourniquet (AAJT-S) for Non-compressible Torso Haemorrhage · recruiting
- NCT06704997 — Machine Learning to Predict Factors Affecting Rehabilitation Length of Stay and Healthcare Costs for Neurological Rehabi · active not recruiting
- NCT06305819 — Effectiveness of a Self-management Program After Traumatic Injury · NA · recruiting
Other University Hospital Ostrava trials
Trials by the same sponsor.
- NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
- NCT07374289 — On Scene ECPR in Ostrava · NA · recruiting
- NCT07041086 — Prehospital ECPR in Moravia Silesia Region · recruiting
- NCT07009652 — Optimization of Transport and Use of a Mobile ECMO Team in Patients With Sudden Cardiac Arrest in the Moravian-Silesian · recruiting
- NCT06921746 — Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03588767 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Ostrava
- Last refreshed: 21 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03588767.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing